Intravitreal Bevacizumab for Management of Active Progressive Proliferative Diabetic Retinopathy (PDR)
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Study ID
- NCT00370721
- Phase
- PHASE3
- Status
- Unknown
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- bevacizumab — DRUG
Study Details
To evaluate the effect of intravitreal bevacizumab on the course of diabetic retinopathy in cases with the signs of active progressive PDR
Key Dates
- First listed
- Sep 1, 2006
- Start date
- Mar 31, 2006
- Status verified
- Jun 2008
Study Design
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: I
Primary Outcome Measure
Regression of diabetic retinopathy
Central Contacts
- Hamid Ahmadieh, MD+98 21 22585952
Related Studies
- National Eye Institute Biorepository for Retinal DiseasesRecruiting · National Eye Institute (NEI) · Bethesda, Maryland
- Clinical Applications of Advanced Ophthalmic ImagingRecruiting · University of Miami · Miami, Florida
- Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)Recruiting · University of Alabama at Birmingham · Birmingham, Alabama
- Human iPSC for Repair of Vasodegenerative Vessels in Diabetic RetinopathyRecruiting · University of Alabama at Birmingham · Birmingham, Alabama